"10.1371_journal.pone.0114361","plos one","2014-12-15T00:00:00Z","Outi Vaarala; Arja Vuorela; Markku Partinen; Marc Baumann; Tobias L Freitag; Seppo Meri; Päivi Saavalainen; Matti Jauhiainen; Rabah Soliymani; Turkka Kirjavainen; Päivi Olsen; Outi Saarenpää-Heikkilä; Juha Rouvinen; Merja Roivainen; Hanna Nohynek; Jukka Jokinen; Ilkka Julkunen; Terhi Kilpi","Department of Vaccinations and Immune Protection, National Institute for Health and Welfare, Helsinki, Finland; Helsinki Sleep Clinic, Vitalmed Research Centre Helsinki and Haartman Institute, University of Helsinki, Helsinki, Finland; Meilahti Clinical Proteomics Core Facility, Institute of Biomedicine/Biochemistry and Developmental Biology, and NeuroMed Research Program, University of Helsinki, Helsinki, Finland; Department of Bacteriology and Immunology, Haartman Institute, University of Helsinki, Helsinki, Finland and Research Program Unit, Immunobiology, University of Helsinki, Helsinki, Finland; National Institute for Health and Welfare, Public Health Genomics Research Unit, Biomedicum, Helsinki, Finland; Department of Pediatrics, Childrens Hospital, Helsinki University Hospital, Helsinki, Finland; Department of Child Neurology, Oulu University Hospital, Oulu, Finland; Department of Pediatrics, Tampere University Hospital, Tampere, Finland; Department of Chemistry and Biocenter Kuopio, University of Eastern Finland, Joensuu, Finland; Department of Infectious Disease Surveillance and Control, National Institute for Health and Welfare, Helsinki, Finland; Department of Virology, University of Turku, Turku, Finland","Conceived and designed the experiments: OV AV MB MJ JR TLF SM. Performed the experiments: OV AV MB MJ TLF IJ MR RS. Analyzed the data: OV AV PS MB MJ TLF JJ. Contributed reagents/materials/analysis tools: MP PO TK OSH. Wrote the paper: OV AV MB MJ JR TLF SM IJ TK HN JJ MP.","HN received honoraria for technical consultancy from GlaxoSmithKline (GSK), and Pfizer for development of pneumococcal conjugate vaccines. JJ is co-investigator of a nationwide effectiveness study of the ten-valent pneumococcal conjugate vaccine mainly funded by GlaxoSmithKline. MP has been consultant for Bioprojet and UCB Pharma and received funding support and honoraries for lecturing from Bioprojet, GSK, Cephalon, and Leiras/Takeda. T. Kilpi is principal investigator of a nationwide effectiveness study of the ten-valent pneumococcal conjugate vaccine mainly funded by GlaxoSmithKline, and her unit received funding for a clinical trial on the safety and immunogenicity of a prototype pandemic influenza vaccine from Solvay Pharmaceuticals. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. All other authors confirm they have no conflicts of interest. This does not alter the authors adherence to PLOS ONE policies on sharing data and materials.","2014","12","Outi Vaarala","OV",18,TRUE,7,8,7,12,TRUE,TRUE,FALSE,0,NA,FALSE
